Delix Therapeutics Closes $70 Million Series A Financing to Advance Pipeline of Novel Psychoplastogen Therapeutics to Treat Brain Disorders
Funding to rapidly advance Delix's novel non-hallucinatory, take-home, neuroplasticity-promoting candidates into clinical trials to better treat mental illness and other brain disorders at scale
BOSTON, Sept. 27, 2021 -- (Healthcare Sales & Marketing Ne... Biopharmaceuticals, Neurology, Venture Capital Delix Therapeutics
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Brain | Clinical Trials | Funding | Marketing | Men | Neurology | Pharmaceuticals | Venture Capital